

Ryan Dorton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11402922/publications.pdf>

Version: 2024-02-01

13
papers

679
citations

840776

11
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

808
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. <i>Bioconjugate Chemistry</i> , 2019, 30, 1805-1813.	3.6	22
2	Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic. <i>Scientific Reports</i> , 2018, 8, 8943.	3.3	40
3	Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1151-1160.	2.3	10
4	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1998-2008.	4.1	13
5	Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs. <i>Clinical Cancer Research</i> , 2014, 20, 2104-2114.	7.0	24
6	Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship. <i>Bioconjugate Chemistry</i> , 2014, 25, 560-568.	3.6	50
7	Abstract 832: Pre-clinical development of EC1456: A potent Folate targeted Tubulysin SMDC. <i>Cancer Research</i> , 2014, 74, 832-832.	0.9	6
8	Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 336-343.	2.5	42
9	In Vivo Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates. <i>Molecular Pharmaceutics</i> , 2009, 6, 1518-1525.	4.6	60
10	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 918-925.	2.5	65
11	Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue. <i>Cancer Research</i> , 2008, 68, 9839-9844.	0.9	86
12	Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. <i>Cancer Research</i> , 2007, 67, 4434-4442.	0.9	161
13	Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate. <i>Molecular Pharmaceutics</i> , 2007, 4, 659-667.	4.6	100